BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harder MJ, Anliker M, Höchsmann B, Simmet T, Huber-Lang M, Schrezenmeier H, Ricklin D, Lambris JD, Barlow PN, Schmidt CQ. Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. J Immunol 2016;196:866-76. [PMID: 26643478 DOI: 10.4049/jimmunol.1501919] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Dopler A, Guntau L, Harder MJ, Palmer A, Höchsmann B, Schrezenmeier H, Simmet T, Huber-lang M, Schmidt CQ. Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1. J I 2019;202:2082-94. [DOI: 10.4049/jimmunol.1801545] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
2 Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. J Am Soc Nephrol 2018;29:1141-53. [PMID: 29335241 DOI: 10.1681/ASN.2017070738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
3 Fu R. [How I diagnose and treat paroxysmal nocturnal hemoglobinuria]. Zhonghua Xue Ye Xue Za Zhi 2018;39:887-91. [PMID: 30486581 DOI: 10.3760/cma.j.issn.0253-2727.2018.11.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Swinkels M, Zhang JH, Tilakaratna V, Black G, Perveen R, McHarg S, Inforzato A, Day AJ, Clark SJ. C-reactive protein and pentraxin-3 binding of factor H-like protein 1 differs from complement factor H: implications for retinal inflammation. Sci Rep 2018;8:1643. [PMID: 29374201 DOI: 10.1038/s41598-017-18395-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
6 Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol 2020;221:108616. [PMID: 33148511 DOI: 10.1016/j.clim.2020.108616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Yang Y, Denton H, Davies OR, Smith-Jackson K, Kerr H, Herbert AP, Barlow PN, Pickering MC, Marchbank KJ. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. J Am Soc Nephrol 2018;29:1649-61. [PMID: 29588430 DOI: 10.1681/ASN.2017091006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
8 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
9 Matte A, Cappellini MD, Iolascon A, Enrica F, De Franceschi L. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment? Expert Opin Investig Drugs 2020;29:23-31. [PMID: 31847604 DOI: 10.1080/13543784.2020.1703947] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bakshi S, Cunningham F, Nichols EM, Biedzka-Sarek M, Neisen J, Petit-Frere S, Bessant C, Bansal L, Peletier LA, Zamuner S, van der Graaf PH. Mathematical Modelling of Alternative Pathway of Complement System. Bull Math Biol 2020;82:33. [PMID: 32062771 DOI: 10.1007/s11538-020-00708-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mannes M, Dopler A, Huber-Lang M, Schmidt CQ. Tuning the Functionality by Splicing: Factor H and Its Alternative Splice Variant FHL-1 Share a Gene but Not All Functions. Front Immunol 2020;11:596415. [PMID: 33178228 DOI: 10.3389/fimmu.2020.596415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Makou E, Bailey RG, Johnston H, Parkin JD, Hulme AN, Hähner G, Barlow PN. Combining SPR with atomic-force microscopy enables single-molecule insights into activation and suppression of the complement cascade. J Biol Chem 2019;294:20148-63. [PMID: 31719147 DOI: 10.1074/jbc.RA119.010913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 2017;129:970-80. [PMID: 28028023 DOI: 10.1182/blood-2016-08-732800] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 11.7] [Reference Citation Analysis]
14 Harder MJ, Höchsmann B, Dopler A, Anliker M, Weinstock C, Skerra A, Simmet T, Schrezenmeier H, Schmidt CQ. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. Front Immunol 2019;10:1639. [PMID: 31379839 DOI: 10.3389/fimmu.2019.01639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Merinero HM, García SP, García-Fernández J, Arjona E, Tortajada A, Rodríguez de Córdoba S. Complete functional characterization of disease-associated genetic variants in the complement factor H gene. Kidney Int 2018;93:470-81. [PMID: 28941939 DOI: 10.1016/j.kint.2017.07.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
16 Song KH, Jung SY, Park JI, Ahn J, Park JK, Hwang SG, Kim EH, Nam SY, Park S, Ha H, Song JY. Evaluation of Anti-Tumor Effects of Whole-Body Low-Dose Irradiation in Metastatic Mouse Models. Cancers (Basel) 2020;12:E1126. [PMID: 32365904 DOI: 10.3390/cancers12051126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Dopler A, Stibitzky S, Hevey R, Mannes M, Guariento M, Höchsmann B, Schrezenmeier H, Ricklin D, Schmidt CQ. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces. Front Immunol 2021;12:615748. [PMID: 33732239 DOI: 10.3389/fimmu.2021.615748] [Reference Citation Analysis]
18 Mannes M, Dopler A, Zolk O, Lang SJ, Halbgebauer R, Höchsmann B, Skerra A, Braun CK, Huber-Lang M, Schrezenmeier H, Schmidt CQ. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. Blood 2021;137:443-55. [PMID: 33507296 DOI: 10.1182/blood.2020005959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
19 Zwarthoff SA, Berends ETM, Mol S, Ruyken M, Aerts PC, Józsi M, de Haas CJC, Rooijakkers SHM, Gorham RD Jr. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models. Front Immunol 2018;9:1691. [PMID: 30083158 DOI: 10.3389/fimmu.2018.01691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
20 Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. Immunol Rev 2016;274:152-71. [PMID: 27782321 DOI: 10.1111/imr.12475] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 19.8] [Reference Citation Analysis]
21 Lombardi E, Matte A, Risitano AM, Ricklin D, Lambris JD, De Zanet D, Jokiranta ST, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, Zorzi F, De Marco L, De Franceschi L. Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica 2019;104:919-28. [PMID: 30630982 DOI: 10.3324/haematol.2018.198622] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
22 Brodsky RA. Eculizumab: another breakthrough. Blood 2017;129:922-3. [PMID: 28232621 DOI: 10.1182/blood-2017-01-760496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
23 Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, van der Ende A, Sánchez-Corral P, Kuijpers TW, Wouters D. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera. Blood Adv 2019;3:621-32. [PMID: 30804016 DOI: 10.1182/bloodadvances.2018025692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]